Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 86 peer-reviewed journal articles Updated
Nephrology

Orienting Yourself After an Alport Syndrome Diagnosis

At a Glance

Alport syndrome is a genetic condition that damages kidney filters due to abnormal Type IV collagen. While it causes blood and protein to leak into urine, early treatment with medications like ACE inhibitors can significantly delay disease progression and protect long-term kidney health.

Receiving a diagnosis of Alport syndrome can feel like the ground has shifted beneath your feet. It is completely normal to experience a whirlwind of emotions, ranging from deep anxiety about the future to a sense of relief that your symptoms finally have a name [1]. While it is a serious genetic condition, the medical landscape has changed significantly in recent years. Today, many people with Alport syndrome live full, active lives for decades by managing the condition proactively [2][3].

Understanding the “Filter” Problem

At its core, Alport syndrome is a disease of the kidney’s filtration system. Your kidneys contain millions of tiny filters called glomeruli. These filters rely on a specific building block called Type IV Collagen to stay strong and hold their shape [4][5].

In Alport syndrome, a genetic change (mutation) prevents the body from making this collagen correctly [6][7]. Without the right “scaffolding,” the kidney filters become weak and leaky over time. This allows blood (hematuria) and protein (proteinuria) to escape into the urine [8][9]. Because this same collagen is found in the inner ear and the eyes, some people also experience hearing loss or changes in their vision [10][11].

For a deeper dive into the specific genes and inheritance patterns involved, see our page on The Biology and Genetics of Alport Syndrome.

Grounding Facts for the Newly Diagnosed

When a diagnosis is new, it is easy to focus on the worst-case scenarios. Here are four stabilizing facts to help ground your perspective:

01

Standard of Care: Protecting Your Kidneys

Learn about standard treatments for Alport syndrome to protect your kidneys. Discover when to start ACE inhibitors, SGLT2 inhibitors, and lifestyle changes.

02

The Diagnostic Path: Genetic Testing and Biopsy

Learn how Alport syndrome is diagnosed. Understand why genetic testing for COL4A mutations is the new gold standard and when a kidney biopsy is necessary.

The Shift in Care Guidelines

It is important to know that the way doctors treat Alport syndrome has recently changed. Previous guidelines recommended waiting until the kidneys showed signs of stress (like protein leakage) before starting medication. Current consensus now recommends starting treatment much earlier—often at the time of diagnosis for high-risk groups—to protect the kidneys for as long as possible [24][25].

Moving Forward with Confidence

You are not alone in this journey. While Alport syndrome is a lifelong condition, it is a manageable one. By working closely with a nephrologist (kidney specialist) and staying informed about new research, you can take control of your health. Focus on what you can do today: monitor your blood pressure, keep your medical appointments, and lean on your support network as you adjust to this new reality [26][27]. To understand what the road ahead looks like, explore our page on The Journey of Symptoms: More Than Just Kidneys and Survivorship and Planning for the Future.

Common questions in this guide

What causes Alport syndrome?
Alport syndrome is caused by a genetic mutation that prevents the body from properly making Type IV collagen. This missing building block weakens the kidney's filters over time, allowing blood and protein to leak into the urine.
What is the treatment for Alport syndrome?
While there is no cure, medications like ACE inhibitors and ARBs are used to take pressure off the kidneys and delay disease progression. Doctors now recommend starting these protective treatments as early as possible, even before severe symptoms appear.
Is Thin Basement Membrane Nephropathy the same as Alport syndrome?
Doctors now group Thin Basement Membrane Nephropathy under the broader umbrella of Alport syndrome. It represents a milder form on the same genetic spectrum, often progressing much slower but still requiring lifelong monitoring.
Will Alport syndrome affect my hearing or vision?
Yes, because the same Type IV collagen found in the kidneys is also present in the inner ear and eyes, some patients experience hearing loss or vision changes. Regular screenings with specialists are an important part of managing the condition.
Are kidney transplants successful for people with Alport syndrome?
Yes, for individuals whose condition eventually progresses to kidney failure, kidney transplants are generally very successful. The outcomes for Alport syndrome patients are often as good as or better than those with other kidney diseases.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my (or my child's) genetic testing result, and what does it tell us about the likely speed of disease progression?
  2. 2.How soon should we start an ACE inhibitor or other medication to protect the kidneys?
  3. 3.Since this is a spectrum, are my symptoms currently closer to Thin Basement Membrane Nephropathy (TBMN) or classic Alport syndrome?
  4. 4.When should we schedule the first hearing and vision screenings?
  5. 5.What are the latest changes in the clinical guidelines for when to start treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (27)
  1. 1

    The significance of relationships and dynamics in families with a child with end-stage kidney disease: A qualitative study.

    Agerskov H, Thiesson HC, Pedersen BD

    Journal of clinical nursing 2020; (29(5-6)):987-995 doi:10.1111/jocn.15170.

    PMID: 31889347
  2. 2

    Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study.

    Boeckhaus J, Hoefele J, Riedhammer KM, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2022; (37(12)):2496-2504 doi:10.1093/ndt/gfac006.

    PMID: 35022790
  3. 3

    Features of Autosomal Recessive Alport Syndrome: A Systematic Review.

    Lee JM, Nozu K, Choi DE, et al.

    Journal of clinical medicine 2019; (8(2)) doi:10.3390/jcm8020178.

    PMID: 30717457
  4. 4

    A chloride ring is an ancient evolutionary innovation mediating the assembly of the collagen IV scaffold of basement membranes.

    Pedchenko V, Bauer R, Pokidysheva EN, et al.

    The Journal of biological chemistry 2019; (294(20)):7968-7981 doi:10.1074/jbc.RA119.007426.

    PMID: 30923125
  5. 5

    The life cycle of type IV collagen.

    Srinivasan S, Sherwood DR

    Matrix biology : journal of the International Society for Matrix Biology 2025; (139()):14-28 doi:10.1016/j.matbio.2025.04.004.

    PMID: 40306374
  6. 6

    Trimerization profile of type IV collagen COL4A5 exon deletion in X-linked Alport syndrome.

    Koyama Y, Suico MA, Owaki A, et al.

    Clinical and experimental nephrology 2024; (28(9)):874-881 doi:10.1007/s10157-024-02503-9.

    PMID: 38658441
  7. 7

    An overview of the multi-pronged approach in the diagnosis of Alport syndrome for 22 children in Northeast China.

    Zhang L, Sun BC, Zhao BG, Ma QS

    BMC nephrology 2020; (21(1)):294 doi:10.1186/s12882-020-01962-y.

    PMID: 32703181
  8. 8

    Alport syndrome: an update.

    Savige J

    Current opinion in nephrology and hypertension 2025; (34(3)):206-211 doi:10.1097/MNH.0000000000001063.

    PMID: 39840589
  9. 9

    Albumin contributes to kidney disease progression in Alport syndrome.

    Jarad G, Knutsen RH, Mecham RP, Miner JH

    American journal of physiology. Renal physiology 2016; (311(1)):F120-30 doi:10.1152/ajprenal.00456.2015.

    PMID: 27147675
  10. 10

    MACULAR HOLES, VITELLIFORM LESIONS, AND MIDPERIPHERAL RETINOSCHISIS IN ALPORT SYNDROME.

    Thomas AS, Baynham JT, Flaxel CJ

    Retinal cases & brief reports 2016; (10(2)):109-11 doi:10.1097/ICB.0000000000000176.

    PMID: 26200386
  11. 11

    Bilateral giant macular holes: A rare manifestation of Alport syndrome.

    Raimundo M, Fonseca C, Silva R, Figueira J

    European journal of ophthalmology 2019; (29(1)):NP13-NP16 doi:10.1177/1120672118781232.

    PMID: 29873249
  12. 12

    Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?

    Rheault MN, Smoyer WE

    Kidney international 2020; (97(6)):1104-1106 doi:10.1016/j.kint.2020.01.030.

    PMID: 32444091
  13. 13

    Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome.

    Yamamura T, Horinouchi T, Nagano C, et al.

    Kidney international 2020; (98(6)):1605-1614 doi:10.1016/j.kint.2020.06.038.

    PMID: 32712167
  14. 14

    Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?

    Rheault MN

    Kidney international 2020; (98(6)):1400-1402 doi:10.1016/j.kint.2020.07.011.

    PMID: 33276866
  15. 15

    Genotype-Phenotype Correlations for Pathogenic COL4A3-COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome.

    Savige J, Huang M, Croos Dabrera MS, et al.

    Frontiers in medicine 2022; (9()):865034 doi:10.3389/fmed.2022.865034.

    PMID: 35602506
  16. 16

    Glomerular Basement Membrane Protein Expression and the Diagnosis and Prognosis of Autosomal Dominant Alport Syndrome.

    Akihisa T, Sato M, Wakayama Y, et al.

    Kidney medicine 2019; (1(6)):391-396 doi:10.1016/j.xkme.2019.06.007.

    PMID: 32734219
  17. 17

    Comparison between conventional and comprehensive sequencing approaches for genetic diagnosis of Alport syndrome.

    Yamamura T, Nozu K, Minamikawa S, et al.

    Molecular genetics & genomic medicine 2019; (7(9)):e883 doi:10.1002/mgg3.883.

    PMID: 31364286
  18. 18

    Three Novel Heterozygous COL4A4 Mutations Result in Three Different Collagen Type IV Kidney Disease Phenotypes.

    Li A, Gao EZ, Cui YX, et al.

    Cytogenetic and genome research 2018; (154(1)):30-36 doi:10.1159/000486979.

    PMID: 29669314
  19. 19

    Should We Diagnose Autosomal Dominant Alport Syndrome When There Is a Pathogenic Heterozygous COL4A3 or COL4A4 Variant?

    Savige J

    Kidney international reports 2018; (3(6)):1239-1241 doi:10.1016/j.ekir.2018.08.002.

    PMID: 30450445
  20. 20

    Mutation Analysis of Thin Basement Membrane Nephropathy.

    Hirabayashi Y, Katayama K, Mori M, et al.

    Genes 2022; (13(10)) doi:10.3390/genes13101779.

    PMID: 36292665
  21. 21

    AJKD Atlas of Renal Pathology: Thin Basement Membrane Lesion.

    Fogo AB, Lusco MA, Najafian B, Alpers CE

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2016; (68(4)):e17-e18 doi:10.1053/j.ajkd.2016.08.005.

    PMID: 27664478
  22. 22

    [Kidney allotransplantation from alive related donor in patients with Alport syndrome].

    Goriaĭnov VA, Kaabak MM, Babenko NN, et al.

    Khirurgiia 2016; 50-54 doi:10.17116/hirurgia2016150-54.

    PMID: 26977611
  23. 23

    Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation.

    Kashtan CE

    International journal of nephrology and renovascular disease 2018; (11()):267-270 doi:10.2147/IJNRD.S150539.

    PMID: 30410383
  24. 24

    Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.

    Kashtan CE, Gross O

    Pediatric nephrology (Berlin, Germany) 2021; (36(3)):711-719 doi:10.1007/s00467-020-04819-6.

    PMID: 33159213
  25. 25

    Explaining Alport syndrome-lessons from the adult nephrology clinic.

    Mabillard H, Ryan R, Tzoumas N, et al.

    Journal of rare diseases (Berlin, Germany) 2024; (3(1)):14 doi:10.1007/s44162-024-00036-z.

    PMID: 38745975
  26. 26

    Alport Syndrome: A Comprehensive Review.

    Adone A, Anjankar A

    Cureus 2023; (15(10)):e47129 doi:10.7759/cureus.47129.

    PMID: 38021591
  27. 27

    Multidisciplinary Management of Alport Syndrome: Current Perspectives.

    Kashtan C

    Journal of multidisciplinary healthcare 2021; (14()):1169-1180 doi:10.2147/JMDH.S284784.

    PMID: 34045864

This page provides a general overview of an Alport syndrome diagnosis for educational purposes. Always consult your nephrologist or healthcare team for personalized treatment and monitoring plans.

Get notified when new evidence is published on Alport syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.